Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma

Modern Pathology

Volumn 27, Issue 7, 2014, Pages 983-990

  Huang, Hsien Neng ^a,b   Lin, Ming Chieh ^a   Huang, Wen Chih ^c   Chiang, Ying Cheng ^a   Kuo, Kuan Ting ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b CATHAY GENERAL HOSPITAL   (Taiwan)

^c FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

Author keywords

ARID1A; ovarian clear cell carcinoma; PIK3CA; prognosis; PTEN; SWI SNF; ZNF217

Indexed keywords

BRG1 PROTEIN; BRM PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN ARID1A; PROTEIN KINASE B; PROTEIN SMARCB1; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ARID1A PROTEIN, HUMAN; DNA HELICASE; NUCLEAR PROTEIN; SMARCA2 PROTEIN, HUMAN; SMARCA4 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; ZNF217 PROTEIN, HUMAN;

ADULT; AGED; ARID1A GENE; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CLEAR CELL CARCINOMA; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE IDENTIFICATION; GENE LOSS; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ONCOGENE; OVARY CARCINOMA; PIK3CA GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ZNF217 GENE; ADENOCARCINOMA; FEMALE; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; OVARY TUMOR; PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; DNA HELICASES; DNA MUTATIONAL ANALYSIS; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS;

EID: 84903789503     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.216     Document Type: Article

References (37)

1. Anglesio MS, Carey MS, Kobel M, et al. Vancouver Ovarian Clear Cell Symposium Speakers. Clear cell carcinoma of the ovary: A report from the first Ovarian Clear Cell Symposium, 24 June 2010. Gynecol Oncol 2011;121: 407-415
2. Pectasides D, Fountzilas G, Aravantinos G, et al. Advanced stage clear-cell epithelial ovarian cancer: The Hellenic Cooperative Oncology Group experience. Gynecol Oncol 2006;102: 285-291
3. Dallas PB, Pacchione S, Wilsker D, et al. The human SWI-SNF complex protein p270 is an ARID family member with non-sequence-specific DNA binding activity. Mol Cell Biol 2000;20: 3137-3146
4. Phelan ML, Sif S, Narlikar GJ, et al. Reconstitution of a core chromatin remodeling complex from SWI/SNF subunits. Mol Cell 1999;3: 247-253
5. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-Associated ovarian carcinomas. N Engl J Med 2010;363: 1532-1543
6. Fadare O, Renshaw IL, Liang SX. Does the loss of ARID1A (BAF-250a) expression in endometrial clear cell carcinomas have any clinicopathologic significance? A pilot assessment. J Cancer 2012;3: 129-136
7. Zhang X, Zhang Y, Yang Y, et al. Frequent low expression of chromatin remodeling gene ARID1A in breast cancer and its clinical significance. Cancer Epidemiol 2012;36: 288-293
8. Gui Y, Guo G, Huang Y, et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet 2011;43: 875-878
9. Wang DD, Chen YB, Pan K, et al. Decreased expression of the ARID1A gene is associated with poor prognosis in primary gastric cancer. PLoS One 2012;7: E40364
10. Maeda D, Mao TL, Fukayama M, et al. Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma. Int J Mol Sci 2010;11: 5120-5128
11. Kuo KT, Mao TL, Jones S, et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 2009;174: 1597-1601
12. Kuo KT, Mao TL, Chen X, et al. DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma. Clin Cancer Res 2010;16: 1997-2008
13. Dobbin ZC, Landen CN. The importance of the PI3K/ AKT/MTOR pathway in the progression of ovarian cancer. Int J Mol Sci 2013;14: 8213-8227
14. Quinlan KG, Verger A, Yaswen P, et al. Amplification of zinc finger gene 217 (ZNF217) and cancer: When good fingers go bad. Biochim Biophys Acta 2007;1775: 333-340
15. Lee KR, Tavassoli FA, Part J, et al. Surface epithelialstromal tumours. In: Tavassoli FA, Devilee P (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. IARC Press: Lyon; 2003, pp 117-145
16. DeLair D, Oliva E, Kobel M, et al. Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: A study of 155 cases. Am J Surg Pathol 2011;35: 36-44
17. Kobel M, Kalloger SE, Carrick J, et al. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol 2009;33: 14-21
18. Maeda D, Shih I. Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms. Adv Anat Pathol 2013;20: 45-52
19. Kurose K, Zhou XP, Araki T, et al. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol 2001;158: 2097-2106
20. Nakayama K, Nakayama N, Kurman RJ, et al. Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol Ther 2006;5: 779-785
21. Chan JK, Teoh D, Hu JM, et al. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell typeš A study of 1411 clear cell ovarian cancers. Gynecol Oncol 2008;109: 370-376
22. Hashiguchi Y, Tsuda H, Inoue T, et al. PTEN expression in clear cell adenocarcinoma of the ovary. Gynecol Oncol 2006;101: 71-75
23. Clapier CR, Cairns BR. The biology of chromatin remodeling complexes. Annu Rev Biochem 2009;78: 273-304
24. Guan B, Wang TL, Shih I. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res 2011;71: 6718-6727
25. Xiao W, Awadallah A, Xin W. Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma. Int J Clin Exp Pathol 2012;5: 642-650
26. Bosse T, Ter Haar NT, Seeber LM, et al. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer. Mod Pathol 2013;26: 1525-1535
27. Yamamoto S, Tsuda H, Takano M, et al. PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma. Virchows Arch 2012;460: 77-87
28. Yamamoto S, Tsuda H, Takano M, et al. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations. Mod Pathol 2012;25: 615-624
29. Nonet GH, Stampfer MR, Chin K, et al. The ZNF217 gene amplified in breast cancers promotes immortalization of human mammary epithelial cells. Cancer Res 2001;61: 1250-1254
30. Huang G, Krig S, Kowbel D, et al. ZNF217 suppresses cell death associated with chemotherapy and telomere dysfunction. Hum Mol Genet 2005;14: 3219-3225
31. Krig SR, Miller JK, Frietze S, et al. ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells. Oncogene 2010;29: 5500-5510
32. Rahman MT, Nakayama K, Rahman M, et al. Prognostic and therapeutic impact of the chromosome 20q13.2 ZNF217 locus amplification in ovarian clear cell carcinoma. Cancer 2012;118: 2846-2857
33. Cho H, Kim JS, Chung H, et al. Loss of ARID1A/ BAF250a expression is linked to tumor progression and adverse prognosis in cervical cancer. Hum Pathol 2013;44: 1365-1374
34. Katagiri A, Nakayama K, Rahman MT, et al. Loss of ARID1A expression is related to shorter progressionfree survival and chemoresistance in ovarian clear cell carcinoma. Mod Pathol 2012;25: 282-288
35. Rahman M, Nakayama K, Rahman MT, et al. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma. Hum Pathol 2012;43: 2197-2206
36. Ho CM, Lin MC, Huang SH, et al. PTEN promoter methylation and LOH of 10q22-23 locus in PTEN expression of ovarian clear cell adenocarcinomas. Gynecol Oncol 2009;112: 307-313
37. Shimizu T, Tolcher AW, Papadopoulos KP, et al. The clinical effect of the dual-Targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res 2012; 18: 2316-2325